The effect of fingolimod (Fty720) treatment on liver enzyme levels in relapsing-remitting multiple sclerosis patients

Basit Öğe Kaydı
dc.authorscopusid57208693564
dc.authorscopusid55963510600
dc.authorscopusid8944423400
dc.contributor.authorTap, Duygu
dc.contributor.authorTerzi, Menderes Yusuf
dc.contributor.authorDuman, Taşkın
dc.date.accessioned2024-09-19T15:41:33Z
dc.date.available2024-09-19T15:41:33Z
dc.date.issued2020
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractAim: Multiple sclerosis (MS) is a chronic inflammatory pathology affecting the central nervous system. Many therapeutic options have been approved against MS until today. In this study, it was aimed to investigate the effect of fingolimod treatment (FT) on the liver enzyme levels of relapsing-remitting multiple sclerosis (RRMS) patients. Material and Methods: Body mass index, FT (0.5 mg/day) duration, and liver enzyme (alanine aminotransferase, ALT; gamma glutamyl transferase, GGT) levels of 102 RRMS patients (66 female, 36 male, mean age was 40.9±10.9 years) were gathered from polyclinic records retrospectively. Results: The FT duration of MS patients was between 0.5 and 6 years. Increased ALT and GGT levels were detected in RRMS patients after >3 month-long FT. After FT, ALT and GGT levels elevated in males almost 2 times higher than in females. It was observed that ALT and GGT levels increased by 1.3 and 1.5 times in females, while 1.6 and 1.9 times in males, respectively. Of the MS patients with increased transaminases post-FT, 7 (23.3%) males and 8 (17.4%) females were at upper limit of normal for ALT whereas 9 (34.6%) males and 14 (32.6%) females as for GGT. Age and FT duration did not affect ALT and GGT levels. Conclusion: Overall, FT elevated ALT and GGT levels of RRMS patients. Thus, it is of high importance to monitor MS patients throughout FT. So that, we suggest tracking ALT and GGT levels during and after FT to prevent possible liver damage or the occurrence of other systemic diseases. © 2020, Duzce University Medical School. All rights reserved.en_US
dc.identifier.doi10.18678/dtfd.775966
dc.identifier.endpage179en_US
dc.identifier.issn1307-671X
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85098774577en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage175en_US
dc.identifier.trdizinid442592en_US
dc.identifier.urihttps://doi.org/10.18678/dtfd.775966
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/442592
dc.identifier.urihttps://hdl.handle.net/20.500.12483/14326
dc.identifier.volume22en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherDuzce University Medical Schoolen_US
dc.relation.ispartofDuzce Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectALTen_US
dc.subjectFingolimoden_US
dc.subjectGGTen_US
dc.subjectLiver enzymeen_US
dc.subjectRelapsing-remitting multiple sclerosisen_US
dc.titleThe effect of fingolimod (Fty720) treatment on liver enzyme levels in relapsing-remitting multiple sclerosis patientsen_US
dc.title.alternativeFingolimod (Fty720) tedavisinin relapsing-remitting multipl skleroz hastalarında karaciğer enzim düzeylerine etkisien_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu